Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.
Flawless balance sheet with proven track record.
Share Price & News
How has Abiomed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABMD's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ABMD underperformed the US Medical Equipment industry which returned -4.5% over the past year.
Return vs Market: ABMD underperformed the US Market which returned -10.7% over the past year.
Price Volatility Vs. Market
How volatile is Abiomed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHere's Why I Think Abiomed (NASDAQ:ABMD) Is An Interesting Stock
3 weeks ago | Simply Wall StCalculating The Fair Value Of Abiomed, Inc. (NASDAQ:ABMD)
1 month ago | Simply Wall StHere's What We Think About Abiomed, Inc.'s (NASDAQ:ABMD) CEO Pay
Is Abiomed undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ABMD ($144.62) is trading below our estimate of fair value ($165.34)
Significantly Below Fair Value: ABMD is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ABMD is good value based on its PE Ratio (26.7x) compared to the Medical Equipment industry average (39x).
PE vs Market: ABMD is poor value based on its PE Ratio (26.7x) compared to the US market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: ABMD is poor value based on its PEG Ratio (5.8x)
Price to Book Ratio
PB vs Industry: ABMD is overvalued based on its PB Ratio (6.2x) compared to the US Medical Equipment industry average (3x).
How is Abiomed forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABMD's forecast earnings growth (4.6% per year) is above the savings rate (1.7%).
Earnings vs Market: ABMD's earnings (4.6% per year) are forecast to grow slower than the US market (12.3% per year).
High Growth Earnings: ABMD's earnings are forecast to grow, but not significantly.
Revenue vs Market: ABMD's revenue (11.7% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: ABMD's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABMD's Return on Equity is forecast to be low in 3 years time (15.5%).
How has Abiomed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABMD has high quality earnings.
Growing Profit Margin: ABMD's current net profit margins (29.1%) are lower than last year (30.1%).
Past Earnings Growth Analysis
Earnings Trend: ABMD's earnings have grown significantly by 30.2% per year over the past 5 years.
Accelerating Growth: ABMD's earnings growth over the past year (10.5%) is below its 5-year average (30.2% per year).
Earnings vs Industry: ABMD earnings growth over the past year (10.5%) exceeded the Medical Equipment industry 1%.
Return on Equity
High ROE: ABMD's Return on Equity (23.4%) is considered high.
How is Abiomed's financial position?
Financial Position Analysis
Short Term Liabilities: ABMD's short term assets ($636.6M) exceed its short term liabilities ($126.3M).
Long Term Liabilities: ABMD's short term assets ($636.6M) exceed its long term liabilities ($23.5M).
Debt to Equity History and Analysis
Debt Level: ABMD is debt free.
Reducing Debt: ABMD has not had any debt for past 5 years.
Debt Coverage: ABMD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ABMD has no debt, therefore coverage of interest payments is not a concern.
Inventory Level: ABMD has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ABMD's debt is covered by short term assets.
What is Abiomed's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ABMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Minogue (52yo)
Mr. Michael R. Minogue, also known as Mike, has been Chief Executive Officer and President of ABIOMED Europe GmbH since April 2004. Mr. Minogue has been Chief Executive Officer, President and Director of A ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD19.24M) is above average for companies of similar size in the US market ($USD7.33M).
Compensation vs Earnings: Mike's compensation has increased by more than 20% in the past year.
|CFO & VP||2yrs||US$3.21m||0.00086% $56.0k|
|Senior VP & COO||13yrs||US$4.41m||0.29% $18.9m|
|VP & GM of Global Sales||11.08yrs||US$2.88m||0.10% $6.6m|
|VP & Chief Commercial Officer||1yr||US$2.86m||0.096% $6.3m|
|VP & Corporate Controller||12.42yrs||US$1.49m||0.0012% $76.2k|
|Chief Technology Officer||no data||no data||no data|
|Director of Investor Relations||5.58yrs||no data||no data|
|VP, General Counsel & Secretary||2.25yrs||no data||no data|
|Head of Global Human Resources||0.58yr||no data||no data|
Experienced Management: ABMD's management team is seasoned and experienced (5.5 years average tenure).
|Independent Director||11.92yrs||US$267.16k||0.42% $27.1m|
|Independent Director||4.17yrs||US$267.16k||0.015% $1.0m|
|Independent Director||8.92yrs||US$269.66k||0.017% $1.1m|
|Director Emeritus||3.67yrs||US$254.66k||no data|
|Independent Director||5.67yrs||US$259.66k||0.029% $1.9m|
|Lead Director||14.5yrs||US$294.66k||0.073% $4.8m|
|Independent Director||4.17yrs||US$264.66k||0.012% $804.7k|
Experienced Board: ABMD's board of directors are considered experienced (7.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Abiomed, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Abiomed, Inc.
- Ticker: ABMD
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$6.511b
- Shares outstanding: 45.06m
- Website: https://www.abiomed.com
Number of Employees
- Abiomed, Inc.
- 22 Cherry Hill Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ABMD||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 1987|
|AIO||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 1987|
|0H7S||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 1987|
|AIO||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Jul 1987|
|ABMD *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 1987|
|A1BM34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 4 REPR 1 COM||BR||BRL||Jan 2020|
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company engages in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/02 07:51|
|End of Day Share Price||2020/04/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.